TrialCancer discovery2013

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Jim Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.